Talazoparib demonstrated critical antileukemic efficacy as a single-agent and in combination with decitabine in several MDS/CMML and AML cell samples, which might be mediated by the formation of cytotoxic PARP1-DNA complexes [27], DNMT1-DNA complexes [38], and PARP1-DNMT1-DNA complexes [28], respectively. This evidence concerns the gene DNMT1 and chronic myelomonocytic leukemia.